**Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up**

Novella Pugliese 1,* M., Marco Picardi 1,* Roberta Della Pepa 1,* Claudia Giordano 1,* Francesco Muriano 1, Aldo Leone 1, Giuseppe Delle Cave 1, Alessandro D’Ambrosio 1, Violetta Marafioti 1, Maria Gabriella Rascato 1, Daniela Russo 2, Massimo Mascolo 2,* and Fabrizio Pane 1

1 Department of Clinical Medicine and Surgery, Hematology Section, University of Naples “Federico II”, Via Sergio Pansini, 5, 80131 Naples, Italy; marco.picardi@unina.it (M.P.); robertadellapepa@gmail.com (R.D.P.); claudiagiordano91@hotmail.com (C.G.); francesco.muriano@gmail.com (F.M.); aldo.leone93@libero.it (A.L.); giusedellecave87@gmail.com (G.D.C.); alexander.dambrosio@gmail.com (A.D.); violetta.marafioti@hotmail.it (V.M.); mg.rascato@gmail.com (M.G.R.); fabrizio.pane@unina.it (F.P.)

2 Pathology Section, Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Via Sergio Pansini, 5, 80131 Naples, Italy; daniela.russo@unina.it (D.R.); massimo.mascolo@unina.it (M.M.)

* Correspondence: novypugliese@yahoo.it; Tel.: +39-0817462037

**Simple Summary:** The current literature on NLPHEL therapy is scarce due to the disease rarity. Our study aims to focus on the management and treatment strategies of NLPHEL based on risk stratification. This paper contributes to the current literature, based mainly on retrospective studies and on small cohort studies, confirming the benefit of Rituximab for patients with NLPHEL, in particular for those with advanced disease. We hope that our results can be confirmed by larger cohort studies from the research community.

**Abstract:** Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHEL) is a rare variant of HL that accounts for 5% of all HL cases. The expression of CD20 on neoplastic lymphocytes provides a suitable target for novel treatments based on Rituximab. Due to its rarity, consolidated and widely accepted treatment guidelines are still lacking for this disease. Methods: Between 1 December 2007 and 28 February 2018, sixteen consecutive newly diagnosed adult patients with NLPHEL received Rituximab (induction ± maintenance)-based therapy, according to the baseline risk of German Hodgkin Study Group prognostic score system. The treatment efficacy and safety of the Rituximab-group were compared to those of a historical cohort of 12 patients with NLPHEL who received Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) chemotherapy followed by radiotherapy (RT), if needed, according to a similar baseline risk. The primary outcome was progression-free survival (PFS) and secondary outcomes were overall survival (OS) and side-effects (according to the Common Terminology Criteria for Adverse Events, v4.03). Results: After a 7-year follow-up (range, 1–11 years), PFS was 100% for patients treated with the Rituximab-containing regimen versus 66% for patients of the historical cohort (p = 0.036). Four patients in the latter group showed insufficient response to therapy. The PFS for early favorable and early unfavorable NLPHELs was similar between treatment groups, while a better PFS was recorded for advanced-stages treated with the Rituximab-containing regimen. The OS was similar for the two treatment groups. Short- and long-term side-effects were more frequently observed in the historical cohort. Grade ≥3 neutropenia was more frequent in the historical cohort compared with the Rituximab-group (58.3% vs. 18.7%, respectively; p = 0.03). Long-term non-hematological toxicities were observed more frequently in the historical cohort. Conclusion: Our results confirm the value of Rituximab in NLPHEL therapy and show that Rituximab (single-agent) induction and maintenance in a limited-stage, or Rituximab with ABVD only in the presence of risk factors, give excellent results while sparing cytotoxic agent- and/or RT-related damage. Furthermore, Rituximab inclusion in advanced-stage therapeutic strategy seems to improve PFS compared to conventional chemo-radiotherapy.
Keywords: nodular lymphocyte predominant hodgkin lymphoma; rituximab; progression-free survival

1. Introduction

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare HL subtype since it represents approximately 5% of all cases [1]. Although NLPHL is characterized by multiple and late relapses, it is acknowledged as having a more indolent course and potentially a better prognosis compared with classical HL (cHL) [2,3].

Treatment choice is based on the disease stage and may include radiation therapy (RT) with or without chemotherapy (CT), borrowing approaches and strategies from cHL [4]. The current National Comprehensive Cancer Network [4] and European Society for Medical Oncology [5] guidelines recommend using RT alone for first-line therapy of patients with non-bulky early stage NLPHL, and CT using an ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) [6] or CHOP (Cyclophosphamide, Doxorubicin, Vincristine and oral Prednisolone) regimen plus RT for most advanced-stages. Considering possible recurrences requiring further therapies in NLPHL, a less toxic treatment schedule would be desirable in order to reduce treatment-related mortality and morbidity.

From this consideration, the different phenotypes of expression on the cell of origin (“popcorn” cells or lymphocyte-predominant (LP) cells in NLPHL is a feature of CD20 and CD79a expression, unlike Hodgkin-Reed-Sternberg cHL cells), provides the rationale for the inclusion of the anti-CD20 antibody Rituximab in the treatment schemes of this disease, as a low toxic component able to replace CT and/or RT in order to reduce observed toxicity. Rituximab use is widely consolidated in the treatment of B-cell non-Hodgkin lymphoma, while its role in the treatment schedule for all stages of NLPHL is still not clear. Anti-CD20 antibody treatment with Rituximab showed impressive activity in relapsed NLPHL, as proven by studies from the German Hodgkin Study Group (GHSG) and the Stanford group [7–9]. More recently, the GHSG conducted a single-arm phase 2 study to evaluate efficacy and safety of Rituximab as single agent in patients with newly diagnosed stage I-A NLPHL [10]. Little is known about the role and optimal schedule of the administration of anti-CD20 antibodies in the induction treatment of NLPHL in all the different stages.

To shed more light on the best front-line treatment for NLPHL, we conducted a retrospective study in patients with this entity who were referred to our institution for therapy based on Rituximab (Rituximab-containing group) between 1 December 2007 and 28 February 2018. We compared the progression-free survival (PFS) and overall survival (OS) of these patients with those of a historical cohort of NLPHL patients, previously referred to our institution for therapy based on combined modality treatment (anthracycline-containing CT plus RT) or on only anthracycline-containing CT during the period between 1 October 2001 and 30 November 2007. In addition, great attention was paid to the occurrence of therapy-related side-effects. These data were partially previously described [11]; here, we report an increasing number of patients treated in the Rituximab-containing group with a longer follow-up.

2. Results

2.1. Patients Characteristics

The demographic and clinical characteristics of the analyzed patients are reported in Table 1; the relative frequencies of patient features in the two groups were compared and were similar for adverse prognostic factors. Risk-adapted strategies for historical cohort and Rituximab-containing group are summarized in Table 2 and described in the Materials and Methods section.
Risk factors according to the Germany Hodgkin Study Group:

1. mediastinal mass larger than one-third of the maximum thoracic width;
2. extra-nodal disease;
3. elevated erythrocyte sedimentation rate (ESR): >50 mm/h without B symptoms or >30 mm/h with B symptoms (B symptoms: fever, night sweat, unexplained weight loss >10% over 6 months);
4. Nodal areas: involvement of ≥3 nodal areas.

Early favorable: clinical stage (CS) I-II without risk factors; early unfavorable: CS I-II with ≥1 risk factors; advanced-stage: CS stage IIB with large mediastinal mass and/or extranodal disease and CS III-IV.

**Table 1.** Clinical features of the two cohorts of patients: historical cohort versus Rituximab-containing cohort.

| Clinical Features | Historical Cohort (n = 12) | Rituximab-Containing Cohort (n = 16) | \( p \) Value |
|------------------|---------------------------|------------------------------------|--------------|
| Age (median; range) years | 33 (19–56) | 36 (21–69) | 0.30 |
| Sex | | | |
| Males | 11 (91.7) | 16 (100) | 0.88 |
| Stage | | | |
| I | 6 (50) | 4 (25) | 0.17 |
| II | 3 (25) | 5 (31.25) | 0.72 |
| III | 2 (16.7) | 5 (31.25) | 0.38 |
| IV | 1 (8.3) | 2 (12.5) | 0.72 |
| B symptoms | | | |
| No | 7 (70) | 12 (75) | 0.50 |
| Yes | 5 (30) | 4 (25) | 0.35 |
| Treatment groups | | | |
| Early favorable | 4 (33.3) | 6 (37.5) | 0.82 |
| Early unfavorable | 5 (41.7) | 3 (18.75) | 0.18 |
| Advanced-stage | 3 (25) | 7 (43.75) | 0.30 |

Note: Unless otherwise indicated, data are number of patients, with percentage in parentheses.

**Table 2.** Risk-adapted strategies for historical cohort and Rituximab-containing cohort.

| Treatment Groups | Historical Cohort | Rituximab-Containing Cohort |
|------------------|-------------------|-----------------------------|
| Early favorable (limited-stage) | ABVD x 4 cycles + IF-RT (30 Gy) (limited-stage, \( n = 4 \); Intermediate-stage, \( n = 5 \)) | Weekly induction Rituximab x 4 weeks + Rituximab maintenance (Rituximab once every 3 months for two years) (\( n = 6 \)) |
| Early unfavorable (intermediate-stage) | | ABVD x 4 cycles combined with monthly Rituximab x 4 months (on day 1 of each ABVD cycle) (\( n = 3 \)) |
| Advanced-stage | ABVD x 6 cycles (\( n = 3 \)) | ABVD x 6 cycles combined with Rituximab every two weeks for 6 months (on day 1 and 15 of each ABVD cycle) (\( n = 7 \)) |

**ABVD [6]**
- Doxorubicin: 25 mg/m\(^2\) IV days 1 and 15
- Bleomycin: 10 mg/m\(^2\) IV days 1 and 15
- Vinblastine: 6 mg/m\(^2\) IV days 1 and 15
- Dacarbazine: 375 mg/m\(^2\) IV days 1 and 15

**Rituximab [12]**
- 375 mg/m\(^2\) IV

Risk factors according to the Germany Hodgkin Study Group:

1. mediastinal mass larger than one-third of the maximum thoracic width;
2. extra-nodal disease;
3. elevated erythrocyte sedimentation rate (ESR): >50 mm/h without B symptoms or >30 mm/h with B symptoms (B symptoms: fever, night sweat, unexplained weight loss >10% over 6 months);
4. Nodal areas: involvement of ≥3 nodal areas.

Early favorable: clinical stage (CS) I-II without risk factors; early unfavorable: CS I-II with ≥1 risk factors; advanced-stage: CS stage IIB with large mediastinal mass and/or extranodal disease and CS III-IV.
2.2. Outcome Measures and Survival

Overall, 27 of the 28 enrolled patients obtained a complete remission (CR) to first-line therapy. One patient in the historical cohort showed insufficient response to front-line therapy and was considered as primary refractory.

The median follow-up for the entire study population was 7 years (range 1–11 years) and did not differ between the historical cohort (median follow-up 7.7 years, range 4–11 years) and Rituximab-containing group (median follow-up 6.6 years, range 1–11 years; \( p = 0.14 \)).

During the follow-up period, one relapse in the early stage sub-set and two relapses in the advanced-stage sub-set were observed in the historical cohort, while none of the patients among the Rituximab-containing group showed relapses. Thus, NLPHL patients treated with Rituximab-containing risk-adapted protocol showed a better 7-year PFS compared with historical cohort (100% vs. 66.7, respectively; (95% confidence interval—CI 44.7–100), \( p = 0.036 \); Figure 1a). In particular, among the advanced-stage patients, the median PFS was 23.8 months for patients of the historical cohort compared with median PFS (not reached) for patients treated according to the Rituximab-containing protocol \( (p = 0.002, \text{Figure 1b}) \).

In contrast, no differences in terms of PFS between treatment protocols were found for early favorable \( (p = 0.62, \text{Figure 1c}) \) and early unfavorable \( (p = 1, \text{Figure 1d}) \) patients.

Figure 1. Outcome according to the treatment protocol. (a) Comparison of progression-free survival (PFS) for the two treatment groups, Rituximab-containing (R-containing) and Rituximab-free (R-free); (b) comparison of PFS for advanced-stages; (c) comparison of PFS for early unfavorable stages; (d) comparison of PFS for early favorable stages.
The OS was similar for the two treatment groups, with only one event in the Rituximab-containing group ($p = 0.39$, Figure 2). This patient had documented CR at the one-month assessment after the last dose of scheduled immunochemotherapy but died due to bleomycin-induced pneumonitis.

**Figure 2.** Comparison of overall survival (OS) for the two treatment groups, Rituximab-containing (R-containing) and Rituximab-free (R-free).

Short- and long-term side-effects (according to the Common Terminology Criteria for Adverse Events—CTCAE, version 4.03) were more frequently observed in the historical cohort. Grade 3–4 neutropenia was more frequent in the historical cohort compared with the Rituximab-containing group (58.3% vs. 18.7%, respectively; $p = 0.03$). Long-term non-hematological toxicities were more frequently observed in the historical cohort. Among the 12 cases, six suffered from thyroid disease, two from lung fibrosis, two from avascular necrosis of the femoral head, and one from valvular heart disease (most likely related to irradiation). One patient in the rituximab group died after induction immunochemotherapy due to bleomycin-induced pneumonitis.

3. Discussion

In this study, the outcomes of two consecutive series of patients with NLPHL, one comprising 12 patients (historical cohort) and the other including 16 patients, were compared. The first series received an induction treatment with either classical combined modality treatment, i.e., a CT/RT combination, or a full-course of CT alone. The second series received front-line Rituximab-containing risk-adapted treatment. All of the 16 patients (100%) who received Rituximab-containing treatment achieved CR at restaging, while one out of the 12 patients who were treated with the classical strategy (ABVD ± RT) showed refractory disease. At diagnosis, this patient had advanced-stage disease with right cervical, obturator and iliac nodal localizations and three risk factors according to the International Prognostic Score (IPS) (fair risk) [13].

Despite the more indolent clinical behavior of NLPHL and the more favorable prognosis, particularly for patients with early stage disease, compared to cHL, late and occasionally multiple relapses are frequently observed [2,14,15]. Therefore, there is a need for breakthrough treatment advances that, along with low toxicity, demonstrate greater efficacy in improving overall prognosis. Due to its rarity, there is no wide consensus as regards induction therapy for NLPHL.
Outcomes from the principal studies reported in the setting of early stage and advance-stage NLPHLs are summarized in Tables 3 and 4.

**Table 3.** Selected studies in early stage NLPHL, showing the relatively small number of patients treated with Rituximab-containing regimens.

| Author, Year       | Study Type | Reported Case | Stage | Treatment (Percentage of Patients) | PFS | OS | Median Follow-Up, Years | Adverse Events Grade ≥ 3 (Percentage of Patients) |
|--------------------|------------|---------------|-------|------------------------------------|-----|----|------------------------|-----------------------------------------------|
| Present Study, 2021| Retrospective | 18            | I–II  | CMT (50) RI + RM/R + CT (50)       | 89  | 100 | 7                      | Early + Late (55) Early (11)                  |
| Wilder, 2002 [16]  | Retrospective | 48            | I–II  | RT (100)                           | 82% | 83% | 9                      | Late (7)                                     |
| Feugier, 2004 [17] | Prospective | 42            | I–II  | CMT (100)                          | 80% | 86% | 15                     | nr                                           |
| Nogovà, 2005 [18]  | Retrospective | 131           | I     | RT (69) CMT (31)                   | 96% | 100%| 4                      | Early + late (7) Early + late (49)            |
| Wirth, 2005 [19]   | Retrospective | 202           | I     | RT (100)                           | 82% | 83% | 15                     | Late (16)                                    |
| Chen, 2010 [20]    | Retrospective | 113           | I–II  | CT (6) RT (94)                     | 14% | 83% | 11 years               | nr                                           |
| Savage, 2011 [21]  | Retrospective | 88            | I–II  | RT (36) CMT (64)                   | 65% | 84% | 5                      | nr                                           |
| Advani, 2014 [12]  | Prospective | 14            | I–II  | RI (43) CMT (57)                   | 42% | 100%| 9.5                    | nr                                           |
| Eichenauer, 2015 [22] | Retrospective | 256           | I     | CMT (28) RT (61) RI (11)          | 88% | 90% | 8 years                | Late (11) Late (6) Late (4)                  |
| Monteith, 2018 [23] | Prospective | 29            | I–II  | CT CMT                            | 85% | 95% | 10                     | nr                                           |
| Alonso, 2018 [24]  | Retrospective | 1420          | I–II  | Observation (13) CT (22) CMT (25) | 87% | 93% | 4                      | nr                                           |
| Pinnix, 2019 [25]  | Retrospective | 71            | I–II  | RT (51) CMT (41) CT (8)           | 93% | 100%| 6                      | Late (8) Late (17) nr                        |
| Borchmann, 2019 [26] | Retrospective | 121           | I–II  | Observation (19) RT (61) CMT (11) | 65% | 94% | 6                      | nr                                           |
| Posthuma, 2019 [27] | Retrospective | 441           | I–II  | CT (4) CMT (11) RI (1) Observation (27) | 84% | 90% | 8                      | nr                                           |
| Eichenauer, 2020 [28] | Prospective | 28            | I     | RT (100)                          | 51% | 91% | 10                     | Late (11)                                   |
| Binkley, 2020 [29] | Retrospective | 559           | I–II  | RT (46) CMT (33) CT (8) Observation (7) RI + RT (3) | 91.1% | 99.4% | 5.5 | Early + Late (5) Early + late (4) Early + late (17) nr |

RT: radiotherapy; CMT: combined modality treatment; CT: chemotherapy; R: rituximab; I: induction; M: maintenance. * Early adverse events of grade 3 are reported together with grades 1 and 2; OS: overall survival.
Table 4. Selected studies in advanced-stage NLPHL, showing the relatively small number of patients treated with Rituximab-containing regimens.

| Author, Year | Study Type | Reported Case | Ann-Arbor Stage | Treatment (Percentage of Patients) | Median Follow-Up, Years | PFS | OS | Adverse Events Grade ≥3 (Percentage of Patients) |
|--------------|------------|---------------|-----------------|-----------------------------------|------------------------|-----|----|---------------------------------|
| Present Study, 2021 | Retrospective | 10 | III–IV | CT (30) R + CT (70) | 2 | 33% | 100% | 85% | Early (67) Early + late (43) |
| Xing, 2014 [30] | Retrospective | 42 | III–IV | CT (100) | 11 | 82% | 89% | Early * + late * (12.5) |
| Ames, 2015 [31] | Retrospective | 8 | III–IV | CT (100) | 8 | 47% | nr | nr |
| Shankar, 2014 [32] | Retrospective | 41 | III–IV | R ± CT | 7 | 78% | 98% | nr |
| Fanale, 2017 [33] | Retrospective | 22 | III–IV | R + CT | 7 | 86% | nr | nr |
| Prusila, 2018 [34] | Retrospective | 9 | III–IV | R + Bendamustine | 3 | 100% | 100% | nr |
| Borchmann, 2019 [26] | Retrospective | 42 | III–IV | Observation (33) RT (2) CT (33) CT + R (32) | 6 | 90% | 100% | 100% | 100% | 63% | 97% | 97% | 97% | nr |
| Eichenauer, 2020 [35] | Retrospective | 144 | III–IV | CMT (100) | 10 | 70% | 87% | Early * + late * (15.3) |
| Eichenauer, 2020 [36] | Prospective | 84 | III–IV | PET2 negative CT (65) PET2 positive CT (22.6) PET2 positive R + CT (14.3) | 5 | 90.2% | 67.5% | nr | Late (12) |

RT: radiotherapy; CMT: combined modality treatment; CT: chemotherapy; R: rituximab. * Only adverse events leading to death are reported. PET2: positron emission tomography performed after two cycles of chemotherapy.

For patients with stage I-II NLPHL, RT, either alone or in combination with anthracycline-containing CT, has been the mainstay of treatment, and several studies have reported very good outcomes, with the 10-year PFS being >80% [4,18,20,21], similar to that reported in our series for both treatment groups.

Advani et al. reported the results of a phase II study of Rituximab induction with or without Rituximab maintenance in both previously treated and untreated NLPHL. In the setting of 21 newly diagnosed patients, the estimated 5-year PFS was 41.7% vs. 51.9% for patients treated with Rituximab induction vs. Rituximab induction + maintenance, respectively (median PFS 1.9 vs. 5.6 years, p = 0.37), with a trend for better PFS for patients with stages I–II compared with stage III (median PFS 5.8 vs. 1.8 years, respectively) [12]. In this trial, however, the early stage group also included patients with risk factors. Our results underline the importance of therapy stratification on the basis of risk at baseline and indicate that the patients with risk factors deserve CT, while a prolonged exposure to Rituximab is sufficient to guarantee long lasting protection against disease recurrence for those patients with very limited stage disease. In fact, in our series, we restricted the use of Rituximab as a single agent only to the patients at stages I and II without risk factors. However, in order to reduce the possibility of relapses, we prolonged the anti-CD20 antibody treatment with further eight infusions (once every three months), distributed over two-year maintenance therapy. Therefore, as seen in indolent B-cell non-Hodgkin lymphomas, the use of Rituximab maintenance seems to either delay or avoid relapses, with the PFS being similar for patients with early favorable NLPHL treated either with combined CT/RT modalities or the Rituximab-containing regimen (Figure 1d). This similarity in PFS was confirmed after a long follow-up: the median follow-up for early stage Rituximab-free-treated patients was 6.5 years with a range of 3.2–11 years, and 6.25 years with a range of 5.1–11 years for early favorable patients undergoing Rituximab induction + maintenance.

In a phase II trial from the GHSG, investigating Rituximab monotherapy in newly diagnosed stage I-A NLPHL, the 4-year PFS was 77.1% [10]. Although Rituximab was
shown to be an active and safe single agent in the treatment of NLP HL, the authors
remarked the better PFS reported for patients with early stage disease treated with RT
(5-year PFS 95%) [2,20] or CT [21], suggesting that Rituximab alone is less effective than
RT or CT. In this study, the role of Rituximab maintenance was not explored and despite
an initial impressive overall response rate (ORR) of 100% with CR observed in 24 of the
28 patients, the short time frame Rituximab exposure appears to be insufficient to preclude
the likelihood of continuous early relapses, as indicated by PFS rates of 96.4%, 85.3% and
81.4% at 12, 24, and 36 months, respectively, and the 25% total disease recurrences observed
in the study. The difference in terms of PFS from our study is likely to be related to the results
from the use of maintenance Rituximab in our cohort. Secondary malignancies
were the most frequent cause of death among patients treated with RT [20] (Tables 3 and 4).
However, in this cohort of 28 patients described by Eichenauer et al. [10] and treated only
with Rituximab, two patients, nevertheless, developed secondary malignancies after 2 and
4 years, respectively, from the initial NLP HL diagnosis. RT-related long-term iatrogenic
complications have led to increased exploration of different treatment modalities.

In particular, in order to spare RT-related toxicities, Pinnix et al. [25], in a cohort of
71 NLP HL stage I/II reported no differences in tumor control among patients treated with
extended-field RT (EFRT), involved-field RT (IFRT) and involved-site RT. Similar results
were obtained in GHSG clinical trials in which EFRT was compared with IFRT, leading the
authors to conclude that IFRT is associated with less toxicity and should be preferred over
EFRT [22].

In contrast, Savage et al. reported—in an era-to-era comparison—a better 10-year PFS
for the ABVD regimen (91%) compared with RT alone (65%) for the treatment of early stage
NLP HL [21]. In a more recent retrospective multicenter analysis on 559 NLP HLs, RT and
combined RT/CT treatment showed similar 5-year PFS (91.1% and 90.5%, respectively),
without differences in terms of OS [29].

Taken together, the already available data and results of our study indicate that front-
line Rituximab treatment, when followed by a two-year maintenance therapy, seems to
have a low toxicity and a high efficacy in treating patients with early stage NLP HL without
risk factors. These data need to be confirmed in a larger study population cohort at a time
when there is more evidence for the use of limited field RT.

In the remaining patients of our series, according to a risk-adapted treatment approach,
we combined Rituximab therapy to polychemotherapy, giving a total of four cycles of ABVD
to the patients at stage I and II but with one or more risk factors (early unfavorable) and
six cycles of ABVD to those patients who presented advanced-stage (III or IV) disease.
Importantly, the inclusion of Rituximab in early unfavorable cases did not modify the PFS,
but spared patients from RT-related toxicity (Table 3).

Overall, Rituximab was well tolerated in our patients and severe toxic side-effects
were not observed when administered in combination with polychemotherapy, except for
one patient: a 69 year old, with advanced-stage disease, who died in complete remission
after immunochemotherapy due to pneumonitis as a consequence of a bleomycin agent.

Defining the optimal treatment regimen for patients with NLP HL in advanced-stage
is even more challenging [37], and the suitable treatment options include either a B-cell
lymphoma directed CT (CVP (Cyclophosphamide, Vincristine and oral Prednisolone) or
CHOP or bendamustine) [33,34], or ABVD plus or minus Rituximab as valid options [2,20].
Although the use of the R-CHOP-21 regimen seems to be associated with a lower risk of
transformation as late as 20 years after the initial diagnosis [38], the number of patients
treated with R-CHOP is modest (Table 4). Thus, further observations are needed to confirm
this impression. In relation to ABVD, R-CHOP causes more cases of peripheral neuropathy
(with vincristine compared to vinblastine), has a higher cumulative steroid exposure, and a
potentially greater likelihood of infertility (cyclophosphamide vs. dacarbazine). In contrast,
ABVD results in more pulmonary toxicity (bleomycin) and is more difficult to deliver to
elderly patients. In summary, R-CHOP-21 may be a highly effective treatment of patients
with advanced-stage NLP HL, but is not compared prospectively to ABVD [33]. On the
other hand, a preliminary study showed that R-bendamustine is a promising candidate for the therapy of NLPHL, however, the results of this study should be verified in larger prospective trials to confirm the favorable risk-benefit profile of this regimen [34].

In our setting of advanced-stage NLPHL, the introduction of Rituximab appears to provide long-term protection from relapses, as compared with the classical CT/RT approach. Indeed, approximately all of the advanced-stage patients treated with ABVD ± RT and in CR after completion of therapy, relapsed before the end of follow-up. The already described trend toward a continuous pattern of relapse after classical treatment [39] was particularly marked in our patients with advanced-stage presentation. On the other hand, almost all of the patients who received Rituximab-containing therapy remained in CR 7 years after initiation of treatment. These results underscore the role of the anti-CD20 antibody in NLPHL advanced-stage therapy.

Among the seven previously untreated patients with advanced-stage NLPHL who received Rituximab induction ± Rituximab maintenance, reported by Advani et al. [12], despite the ORR of 100%, the median PFS of 22 months achieved in this setting, suggests a short-lived response with Rituximab monotherapy, independent from Rituximab maintenance, and the necessity to use CT [4]. Our results in the setting of advanced-stage disease confirm the importance of CT and suggest an additional role of Rituximab in delaying relapse and durable response.

However, all these treatment modalities are associated with a well-known increased risk of toxicity. In our advanced-stage Rituximab group, one death was recorded due to pneumonitis and the patient was 69 years old, thus, in our opinion, the bleomycin agent could be spared in older patients. In a 18F-fluoro-deoxy-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT)-2 oriented scenario, it would be possible to omit bleomycin or reduce the CT agents of the ABVD scheme, when Rituximab is employed, especially in an elderly population, in which the risk of bleomycin induced pneumonitis and overall infection rates seems to be higher. On the other hand, Eichenauer and Engert recently, in blood 2020, recommend treating patients with advanced-stage NLPHL with a more aggressive therapeutic regimen, i.e., four to six cycles of BEACOPPesc (escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) ± RT [40].

Furthermore, recently, Eichenauer et al. [36], in a PET-2-guided escalated program for advanced stage NLPHL, compared outcomes of PET-2 positive patients after two cycles of chemotherapy, who were randomized to receive six/four additional cycles of eBEACOPP or six additional cycles of eBEACOPP plus rituximab. No differences in terms of 5-year PFS were recorded between the two cohorts (19 patients receiving eBEACOPP (67.5%) and 12 patients receiving additional rituximab (73.3%)). Thus, in PET-2 guided scenarios, Rituximab implementation does not appear to improve outcome, these data need to be further investigated in a larger cohort of patients [36].

Cumulatively, these data suggest that single-agent Rituximab is not appropriate for the treatment of newly diagnosed advanced stage patients as responses are not durable, but it is reasonable to combine rituximab with chemotherapy, including ABVD, to achieve better PFS. The primary limitation of our study is the potential for confounding in a retrospective analysis. It is possible that some uncontrolled variables (interim metabolic imaging, such as FDG-PET/CT scans, RT technique, dose, and fractionation, and/or supportive therapy) could have influenced both treatment utilization and survival in this series, including treatment bias. However, the treatment choice was only influenced by the time-period of the first diagnosis and by stage stratification, thus, reducing the effect of confounding variable. The small number of patients, especially when stratified according to stage and risk factors, represents another limitation of this study, and does not allow us to draw determining conclusions. In the context of this rare disease, it is difficult to conduct studies, although retrospective, on larger cohorts of well-characterized patients, however, data from registries or pooled data from larger study groups or institutions could clarify the role of Rituximab in the first-line treatment of NLPHL. Nevertheless, the long period in which
our patients were followed strengthens the reported data. Given the rarity of NLPHL subtype, we believe that it is unlikely that randomized trials will be conducted in this setting. As a result, we believe that retrospective and well-balanced analyses, such as the current one, can serve an important role in identifying disparities in care and improving patient outcomes.

4. Materials and Methods

Clinical records and outcome of 28 consecutive patients with recent diagnosis of NLPHL followed at the Hematology Unit of the Federico II University of Naples (Italy) were retrospectively analyzed. This analysis compares patients with NLPHL treated with two different risk-adapted strategies over different periods.

The study was approved by the local ethics committee and written informed consent was obtained from the patients.

Lymph node biopsy information reported morphologic, and immunohistochemical features for all analyzed patients. NLPHL histologic diagnosis was performed according to the Rey classification before and after 2008 [41], according to the World Health Organization (WHO) 2008 [42] and 2016 classification [43]. For all patients, lymph node samples obtained by excisional biopsies were available, routinely fixed in formalin and embedded in paraffin (histologic sections stained with hematoxylin and eosin, and Giemsa). All biopsies were retrospectively assessed by two expert hematopathologists with more than 10 years of experience with hematopathological analysis (M.M and D.R.) to confirm the initial NLPHL diagnosis and CD20 expression on neoplastic cells.

All the analyzed patients showed a performance status \(\leq 3\) and were eligible to receive immuno/chemotherapy and/or RT. Patients had a complete anamnesis and underwent physical examination, routine laboratory tests, total-body FDG-PET/CT and bone marrow biopsy; thus, before treatment they were carefully staged according to the Ann-Arbor classification.

Patients were further stratified according to the GHSG in early favorable, early unfavorable and advanced-stage [44] as follows: early favorable, were patients in clinical stage I–II without risk factors; early unfavorable, were patients with clinical stage I–II with at least 1 risk factor among mediastinal mass larger than one-third of the maximum thoracic width; extra-nodal disease; elevated erythrocyte sedimentation rate (ESR) > 50 mm/h without B symptoms or ESR > 30 mm/h with B symptoms (B symptoms: fever, night sweats, unexplained weight loss >10% over 6 months); involvement of \(\geq 3\) nodal areas. Patients with advanced-stage disease were considered to be those in clinical stage IIB with large mediastinal mass and/or extranodal disease, and clinical stages III–IV (Table 2).

The International Prognostic Score was applied to better categorize patients with advanced-stage NLPHL [13].

4.1. Treatment

4.1.1. Historical Cohort Risk-Adapted Strategy

Between 1 October 2001 and 30 November 2007, 12 consecutive patients with NLPHL (historical cohort) were treated, according to their stage, with conventional ABVD regimen (day 1 and day 15 of each cycle of 4 weeks) plus IFRT [6,45]. In particular, all patients in stage I/II received ABVD schedule for four cycles followed by IFRT (30 Gy), while patients in stage III/IV received six cycles of ABVD (Table 2).

4.1.2. Rituximab-Containing Risk-Adapted Strategy

Between 1 December 2007 and 28 February 2018, 16 consecutive adult patients with NLPHL received Rituximab (375 mg/m\(^2\)) intravenous infusion alone or combined with ABVD according to the baseline risk as follows: patients with early favorable disease received Rituximab as a single agent, once per week for four weeks, followed by Rituximab maintenance (once every three months for 2 years); patients with early unfavorable disease received Rituximab once per month plus 4 ABVD cycles; patients with advanced-stage
disease received Rituximab two times per month (on day 1 and 15) for 6 months plus 6 ABVD cycles (Table 2).

4.2. Outcome Measures

The treatment efficacy was assessed after completion according to the 2007 Revised Response Criteria for Malignant Lymphoma [46]. Patients classified as complete responders (disappearance of all evidence of disease) were monitored every 3 months for 24 months and thereafter every 6 months, using clinical-laboratorial examinations, ultrasonography scans and chest radiography [47]. Patients’ follow-up was updated in April 2020.

In the historical cohort, response to treatment was assessed 3 months after the last dose of RT in patients who underwent combined induction treatment with ABVD plus RT, or one month after the last dose of chemotherapy in patients who underwent chemotherapy alone. In the rituximab group, response to treatment was assessed one month after the last dose of rituximab induction (early favorable disease) or one month after the last dose of immunochemotherapy (early unfavorable and advanced-stages).

Short- and long-term treatment related adverse events were recorded and classified according to the CTCAE, v4.03.

4.3. Statistical Considerations

The primary endpoint of this study was to compare the PFS of these two different risk-adapted strategies for the treatment of NLPHL. PFS was defined as the period between treatment start and relapse, progressive disease or the last follow-up visit if none of these events occurred. Secondary endpoints were the OS—defined as the time from diagnosis and the last follow-up visit or death for any cause—and the treatment-related adverse event occurrence and severity.

The Kaplan–Meier method was used to calculate survival; comparisons were made by using the log-rank test. Baseline characteristics and incidence of adverse events were compared using the χ² test; Student’s t-test was also used. All statistical analyses were performed by using R-software, version 3.6.

5. Conclusions

In conclusion, taken together, the already available data and the results of our study indicate that front-line Rituximab induction treatment, when followed by two-year Rituximab maintenance, seems to have a low toxicity and a high efficacy in treating patients with early stage NLPHL without risk factors, replacing previous chemotherapy and/or RT schemes, and sparing the toxicity derived from the use of chemotherapy and/or RT. Furthermore, the combination of anti-CD20 antibodies with the classical ABVD schedule within a risk-adjusted treatment strategy may be used in the therapeutic approach of patients with NLPHL with more aggressive/extensive disease, showing a significant advantage in terms of PFS for advanced-stages.

The small number of patients, especially when these are stratified according to stage and risk factors, constitutes the main limitation of this study, thus, our results need to be confirmed in larger cohort prospective studies.

Author Contributions: Conceptualization, N.P., M.P., R.D.P., M.M. and F.P.; methodology, N.P., M.P., R.D.P.; software, N.P., F.M.; validation, N.P., M.P., R.D.P. and F.P.; formal analysis, N.P., M.P., R.D.P.; investigation, M.P., R.D.P., C.G., F.M., A.L., G.D.C., A.D., V.M., M.M.; resources, M.P., R.D.P., C.G., F.M., A.L., G.D.C., A.D., V.M., M.G.R., D.R., M.M.; data curation, N.P., M.P., R.D.P.; writing—original draft preparation, N.P., M.P., R.D.P. and F.P.; writing—review and editing, N.P., M.P., R.D.P., C.G., F.M., A.L., G.D.C., A.D., V.M., M.G.R., D.R., M.M. and F.P.; visualization, N.P., M.P., R.D.P., C.G., F.M., A.L., G.D.C., A.D., V.M., M.G.R., D.R., M.M. and F.P.; supervision, M.P. and. F.P.; project administration, M.P.; funding acquisition, none. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of University Federico II Naples (protocol code 106/2001 and 15 September 2001).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Morton, L.M.; Wang, S.S.; Devesa, S.S.; Hartge, P.; Weisenburger, D.D.; Linet, M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107, 265–276. [CrossRef]

2. Nogová, L.; Reineke, T.; Brilliant, C.; Sieniawski, M.; Rüdiger, T.; Josting, A.; Bredenfeld, H.; Skripnitchenko, R.; Müller, R.-P.; Müller-Hermelink, H.-K.; et al. Lymphocyte-Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive analysis from the German Hodgkin study group. J. Clin. Oncol. 2008, 26, 434–439. [CrossRef] [PubMed]

3. Diehl, V.; Sextro, M.; Franklin, J.; Hansmann, M.-L.; Harris, N.; Jaffe, E.; Poppema, S.; Harris, M.; Franssila, K.; Van Krieken, J.; et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s Disease and lymphocyte-rich classical Hodgkin’s Disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J. Clin. Oncol. 1999, 17, 776. [CrossRef]

4. Hoppe, R.T.; Advani, R.H.; Ai, W.Z.; Ambinder, R.F.; Armand, P.; Bello, C.M.; Benitez, C.M.; Bierman, P.J.; Boughan, K.M.; Dabaja, B.; et al. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 755–781. [CrossRef]

5. Eichnauer, D.; Aleman, B.; André, M.; Federico, M.; Hutchings, M.; Illidge, T.; Engert, A.; Ladjetto, M. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29, iv19. [CrossRef] [PubMed]

6. Bonadonna, G.; Bonfante, V.; Viviani, S.; Di Russo, A.; Villani, F.; Valagussa, P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s Disease: Long-term results. J. Clin. Oncol. 2004, 22, 2835–2841. [CrossRef]

7. Schulz, H.; Rehwald, U.; Morschhauser, F.; Elter, T.; Driessen, C.; Rüdiger, T.; Borchmann, P.; Schnell, R.; Diehl, V.; Engert, A.; et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008, 111, 109–111. [CrossRef]

8. Eichnauer, D.A.; Plütschow, A.; Schröder, L.; Fuchs, M.; Böll, B.; Von Tresckow, B.; Diehl, V.; Borchmann, P.; Engert, A. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: An analysis from the German Hodgkin Study Group. Blood 2018, 132, 1519–1525. [CrossRef] [PubMed]

9. Ekstrand, B.C.; Lucas, J.B.; Horwitz, S.M.; Fan, Z.; Breslin, S.; Hoppe, R.T.; Natkunam, Y.; Bartlett, N.L.; Horning, S.J. Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood 2003, 101, 4285–4289. [CrossRef] [PubMed]

10. Eichnauer, D.A.; Fuchs, M.; Pluetschow, A.; Klimm, B.; Halbsguth, T.; Böll, B.; Von Tresckow, B.; Nogová, L.; Borchmann, P.; Engert, A. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 2011, 118, 4363–4365. [CrossRef]

11. Della Pepe, R.; Picardi, M.; Giordano, C.; Zacheo, I.; Pugliese, N.; Cerchione, C.; Raimondo, M.; Di Perna, M.; Troncone, G.; Ciancia, G.; et al. Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. Br. J. Haematol. 2018, 182, 715–718. [CrossRef]

12. Advani, R.H.; Horning, S.J.; Hoppe, R.T.; Daadi, S.; Allen, J.; Natkunam, Y.; Bartlett, N.L. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J. Clin. Oncol. 2014, 32, 912–918. [CrossRef] [PubMed]

13. Hasenclever, D.; Diehl, V.; Armitage, J.O.; Assouline, D.; Björkholm, M.; Brusamolino, E.; Canellos, G.P.; Carde, P.; Crowther, D.; Cunningham, D.; et al. A Prognostic score for advanced Hodgkin’s Disease. N. Engl. J. Med. 1998, 339, 1506–1514. [CrossRef]

14. Diehl, V.; Stein, H.; Hummel, M.; Zollinger, R.; Connors, J.M. Hodgkin’s Lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003, 2003, 225–247. [CrossRef] [PubMed]

15. Farrell, K.; McKay, P.; Leach, M. Nodal lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: Evidence from 14-year follow-up in the West of Scotland Cancer Network. Leuk. Lymphoma 2011, 52, 1920–1928. [CrossRef]

16. Wilder, R.B.; Schlembach, P.J.; Jones, D.; Chronowski, G.M.; Ha, C.S.; Younes, A.; Hagemeister, F.B.; Barista, I.; Cabanillas, F.; Cox, J.D. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin’s lymphoma. Cancer 2002, 94, 1731–1738. [CrossRef]

17. Feugier, P.; Labouyrie, E.; Djeridane, M.; Jenabian, A.; Dubruille, V.; Berthou, C.; Ghandour, C.; Desablens, B.; Chait, Y.; Casassus, P.; et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004, 104, 2675–2681. [CrossRef]
18. Nogová, L.; Reineke, T.; Eich, H.T.; Josting, A.; Müller-Hermelink, H.K.; Wingberg, S.; Brantl, C.; Gossmann, A.; Oertel, J.; Bollen, M.V.; et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). *Ann. Oncol.* 2005, 16, 1683–1687. [CrossRef] [PubMed]

19. Wirth, A.; Yuen, K.; Barton, M.B.; Roos, D.; Gogna, K.; Pratt, G.; MacLeod, C.; Bydder, S.; Morgan, G.; Christie, D. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. *Cancer* 2005, 104, 1221–1229. [CrossRef]

20. Chen, R.C.; Chin, M.S.; Ng, A.K.; Feng, Y.; Neuber, D.; Silver, B.; Pinkus, G.S.; Stevenson, M.A.; Mauch, P.M. Early-stage, lymphocyte-predominant Hodgkin’s Lymphoma: Patient outcomes from a large, single-institution series with long follow-up. *J. Clin. Oncol.* 2010, 28, 136–141. [CrossRef]

21. Savage, K.J.; Skinnider, B.; Al-Mansour, M.; Sehn, L.H.; Gascoyne, R.D.; Connors, J.M. Treating limited-stage nodular lymphocyte-predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. *Blood* 2011, 118, 4585–4590. [CrossRef]

22. Eichenauer, D.A.; Plütschow, A.; Fuchs, M.; Von Tresckow, B.; Höll, B.; Behringer, K.; Diehl, V.; Eich, H.T.; Borchmann, P.; Engert, A. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin Lymphoma: A report from the German Hodgkin Study Group. *J. Clin. Oncol.* 2015, 33, 2857–2862. [CrossRef]

23. Monteith, B.; DiMaria, E.C.; Crump, M.; Ames, J.B.; Winter, J.N.; Djurfeldt, M.; Shepherd, L.E.; Meyer, R.M.; Chen, B.E.; Hay, A.E. Limited stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial. *J. Clin. Oncol.* 2018, 36, 7535. [CrossRef]

24. Alonso, C.; Dutta, S.W.; Mitra, N.; Landsburg, D.J.; Zaorsky, N.G.; Grover, S.; Peterson, J.; Trifiletti, D.M. Adult nodular-lymphocyte-predominant Hodgkin lymphoma: Treatment modality utilization and survival. *Cancer Med.* 2018, 7, 1118–1126. [CrossRef]

25. Pinnix, C.C.; Milgrom, S.A.; Cheah, C.Y.; Gunther, J.R.; Ludmir, E.B.; Wogan, C.F.; Nastoupil, L.J.; Neelapu, S.S.; Westin, J.; Lee, H.J.; et al. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. *Blood Adv.* 2019, 3, 1356–1367. [CrossRef]

26. Borchmann, S.; Joffe, E.; Moskowitz, C.H.; Zelenetz, A.D.; Noy, A.; Portlock, C.S.; Gerecitano, J.F.; Batlevi, C.L.; Caron, P.C.; Druillinsky, P.; et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. *Blood* 2019, 133, 2121–2129. [CrossRef] [PubMed]

27. Monteith, B.; DiMaria, E.C.; Crump, M.; Ames, J.B.; Winter, J.N.; Djurfeldt, M.; Shepherd, L.E.; Meyer, R.M.; Chen, B.E.; Hay, A.E. Limited-stage nodular lymphocyte-predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma (cHL) at Princess Margaret Cancer Centre. *Blood* 2017, 126, 3863. [CrossRef]

28. Shankar, A.; Daw, S. Nodular lymphocyte-predominant Hodgkin lymphoma in children and adolescents—A comprehensive review of biology, clinical course and treatment options. *Br. J. Haematol.* 2012, 159, 288–298. [CrossRef] [PubMed]

29. Fanane, M.A.; Cheah, C.Y.; Rich, A.; Medeiros, I.L.; Lai, C.-M.; Oki, Y.; Romaguera, J.E.; Fayad, L.E.; Hagemeister, F.B.; Samaniego, F.; et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma. *Blood* 2017, 130, 472–477. [CrossRef]

30. Prusila, R.E.I.; Haapasaaari, K.-M.; Marin, K.; Pollari, M.; Soini, Y.; Vornanen, M.; Karjalainen-Lindsberg, M.-L.; Turpeenniemi-Hujanen, T.; Kuitiinen, O. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. *Acta Oncol.* 2018, 57, 1265–1267. [CrossRef]

31. Eichenauer, D.A.; Plütschow, A.; Fuchs, M.; Sasse, S.; Baues, C.; Höll, B.; Von Tresckow, B.; Diehl, V.; Borchmann, P.; Engert, A. Long-term follow-up of patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) vs. classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre. *Blood* 2014, 124, 3567–3573. [CrossRef] [PubMed]

32. Binkley, M.S.; Rauf, M.S.; Milgrom, S.A.; Pinnix, C.C.; Tsang, R.W.; Dickinson, M.; Ng, A.K.; Roberts, K.B.; Gao, S.; Balogh, A.G.; et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: A multi-institutional study of adult patients by ILROG. *Blood* 2020, 135, 2365–2374. [CrossRef] [PubMed]

33. Xing, K.H.; Connors, J.M.; Lai, A.; Al-Mansour, M.; Sehn, L.H.; Villa, D.; Klara, R.; Shenker, T.; Gascoyne, R.D.; Skinnider, B.; et al. Advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: A matched pair outcome analysis. *Blood* 2014, 123, 3567–3573. [CrossRef] [PubMed]

34. Ames, J.; Maganti, M.M.; Monteith, B.E.; Hodgson, D.C.; Kukreti, V.; Kuruvilla, J.G.; Prica, A.; Tsang, R.; Sun, R.; Gospodarowicz, M.; et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) vs. classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre. *Blood* 2015, 126, 3863. [CrossRef]

35. Shankar, A.; Daw, S. Nodular lymphocyte-predominant Hodgkin lymphoma in children and adolescents—A comprehensive review of biology, clinical course and treatment options. *Br. J. Haematol.* 2012, 159, 288–298. [CrossRef] [PubMed]

36. Canellos, G.P.; Mauch, P. What is the appropriate systemic chemotherapy for Lymphocyte-Predominant Hodgkin’s Lymphoma? *J. Clin. Oncol.* 2010, 28, e8. [CrossRef] [PubMed]
38. Al-Mansour, M.; Connors, J.M.; Gascoyne, R.D.; Skinnider, B.; Savage, K.J. Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma. *J. Clin. Oncol.* **2010**, *28*, 793–799. [CrossRef]

39. Lazarovici, J.; Dartigues, P.; Brice, P.; Oberic, L.; Gaillard, I.; Hunault-Berger, M.; Brousais-Guillaumot, F.; Gyan, E.; Bologna, S.; Nicolas-Virelizier, E.; et al. Nodular lymphocyte predominant Hodgkin lymphoma: A Lymphoma Study Association retrospective study. *Haematologica* **2015**, *100*, 1579–1586. [CrossRef]

40. Eichner, D.A.; Engert, A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. *Blood* **2020**, *136*, 2987–2993. [CrossRef]

41. Lukes, R.J.; Butler, J.J.; Hicks, E.B. Natural history of Hodgkin’s disease as related to its pathologic picture. *Cancer* **1966**, *19*, 317–344. [CrossRef]

42. Vardiman, J.; Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*; IARC Press: Lyon, France, 2008; ISBN 9789283224310.

43. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* **2016**, *127*, 2375–2390. [CrossRef] [PubMed]

44. Eich, H.T.; Diehl, V.; Görgen, H.; Pabst, T.; Markova, J.; Debus, J.; Ho, A.; Dörken, B.; Rank, A.; Grosu, A.-L.; et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. *J. Clin. Oncol.* **2010**, *28*, 4199–4206. [CrossRef]

45. Brusamolino, E.; Bacigalupo, A.; Barosi, G.; Biñi, G.; Gobbi, P.G.; Levis, A.; Marchetti, M.; Santoro, A.; Zinzani, P.L.; Tura, S. Classical Hodgkin’s lymphoma in adults: Guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. *Haematologica* **2009**, *94*, 550–565. [CrossRef] [PubMed]

46. Cheson, B.D.; Pfistner, B.; Juweid, M.E.; Gascoyne, R.D.; Specht, L.; Horning, S.J.; Coiffier, B.; Fisher, R.I.; Hagenbeek, A.; Zucca, E.; et al. Revised Response Criteria for Malignant Lymphoma. *J. Clin. Oncol.* **2007**, *25*, 579–586. [CrossRef] [PubMed]

47. Picardi, M.; Pugliese, N.; Cirillo, M.; Zeppa, P.; Cozzolino, I.; Giancìa, G.; Pettinato, G.; Salvatore, C.; Quintarelli, C.; Pane, F. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission—A randomized trial of routine surveillance imaging procedures. *Radiology* **2014**, *272*, 262–274. [CrossRef] [PubMed]